Allergopharma GmbH & Co. KG
26
1
1
23
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
3.8%
1 terminated/withdrawn out of 26 trials
95.8%
+9.3% vs industry average
73%
19 trials in Phase 3/4
0%
0 of 23 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
Role: lead
Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study
Role: collaborator
Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials
Role: lead
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Role: lead
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
Role: lead
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
Role: lead
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
Role: lead
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
Role: lead
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
Role: lead
Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis
Role: lead
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
Role: lead
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Role: lead
Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.
Role: lead
Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative
Role: lead
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Role: lead
Efficacy and Safety From a Recombinant Folding Variant of Bet v 1
Role: lead
Efficacy and Safety of a Purified Standardised Wasp Venom Preparation
Role: lead
Open Label Safety Study of a Birch Pollen Allergen Extract
Role: lead
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Role: lead
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis
Role: lead